Coronavirus company news summary – Veracyte and MAVIDx to develop Covid-19 test – PharmaCyte Biotech Covid-19 tests receive CE mark

30 July 2020 (Last Updated July 30th, 2020 09:42)

Veracyte has partnered with MAVIDx for the development of an ultra-high throughput genomic test for Covid-19. MAVIDx will develop, validate, secure regulatory approvals for and commercialise its SARS-CoV-2 and other infectious disease tests, including for influenza, on Veracyte’s diagnostics platform, the nCounter Analysis System. The companies expect to enable Covid-19 testing at around 40,000 samples each day on use nCounter instrument.

Truvian Sciences has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its Easy Check COVID-19 IgM/IgG antibody test. The company is producing the Easy Check test at a mass scale at a manufacturing facility in the US.

PharmaCyte Biotech has announced the Covid-19 tests it has licensed from the Hai Kang Life Corporation have received the CE mark. This mark was awarded to the RT-PCR and ERT-PCR tests. The Declaration of Conformity for the Covid-19 tests has verified that the tests adhere to the Essential Requirements of the European Community’s In-Vitro Diagnostic Medical Device Directive.

Opto Circuits has received orders to deliver pulse oximeters and thermometers from global customers amid the increased demand due to the Covid-19 pandemic. Opto Circuits is currently manufacturing the pulse oximeter, multi para monitor systems and digital thermometers for domestic and global markets under the ‘Make in India’ initiative.